Prostate Cancer VL

Genetic Screening for Patients with Prostate Cancer - Todd Morgan

Details
Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Professor of Urology and has been at...

PSMA-Ligand Uptake in Cervical, Coeliac and Sacral Ganglia as a Pitfall for Lymph Node Metastases in Prostate Cancer Imaging - Christoph Rischpler

Details
( Length of Presentation 7 minutes) Christoph Rischpler presents a study aimed at investigating the PSMA-ligand uptake in PET in cervical, coeliac and sacral ganglia as a pitfall for lymph node metastases in prostate cancer imaging. This patient population consisted of 308 randomly selected patients who underwent Gallium 68 PSMA-PET between October 2012 and March 2014. For image analysis, they det...

Prostate Cancer Awareness Month - David Penson

Details
(Length of Discussion: 20 min) Alicia Morgans and David Penson discuss the relevance of Prostate Cancer Awareness Month and the importance of elevating the awareness for men and their respective caregivers about prostate cancer and other men's health issues and the need to be screened routinely for prostate cancer. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E...

Prostate Cancer Screening is a Shared Decision - Matthew Cooperberg

Details
Alicia Morgans and Matt Cooperberg discuss the controversial topic of how to optimally screen for prostate cancer based on the final recommendations from the U.S. Preventive Services Task Force. Biographies: Matthew Cooperberg, MD, MPH, FACS, UCSF Helen Diller Family Comprehensive Cancer Center Alicia Morgans, MD, MPH Further Related Content: Biomarker Debate: Adopt, Expand, Trust (PRO) HPFS Healt...

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer - Daniel Spratt

Details
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Biographies: Daniel Spratt, MD, Assistant Professor, Vice Chair, Clinical Research Chair, Division of Genitourinary Clinical Research Chief, Genitourinary Radiotherapy Program Department of Radiation Oncology, University of Michigan. Alicia Morgans, MD, MPH Ref...

Personal Prostate Cancer Journey to Raise Funds and Awareness- Sanford Siegel

Details
(Length of Discussion: 4 min) Dr. Sanford J. Siegel, CEO of Chesapeake Urology, has always been an advocate and supporter of prostate cancer screening in men, especially those at high risk. Since 2006, under his leadership, Chesapeake Urology has provided free screenings to Maryland men, mostly in Baltimore City. In this video, Dr. Siegel shares his own prostate cancer story. Biographies: Sanford...

Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens - E. David Crawford

Details
(Length of Presentation: 20 min) Neal Shore, MD, FACS interviews E. David Crawford on a forthcoming paper he authored titled, A ndrogen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Anti-androgens . This paper takes the historical approach in reviewing the treatment of prostate cancer, where we started in the 60's, where we are today and where we hope to be in the futur...

Screening for Prostate Cancer in African American Men - Judd Moul

Details
Prostate cancer in African-American men remains a major public health issue. Judd W Moul, MD, reviews the history of the U.S. Preventive Services Task Force screening guidelines and highlights the US trends and patterns of disparities in cancer mortality among U.S. counties from 1980 to 2014. He touches on the molecular differences that may explain, in part, the aggressiveness of prostate cancer i...

The United States Preventive Services Task Force PSA Screening Recommendations- David Penson

Details
(Length of Discussion: 10 min) David Penson and Alicia Morgans share views on the evolution of the United States Preventive Services Task Force, USPSTF's recommendations for PSA screening. What do the recent changes mean to the clinician and the patient when making individual decisions regarding screening. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd Ch...

Novel Circulating Tumor Cells Blood Assay for the Clarification of 4-10 ng/mL PSA Results - See-Tong Pang

Details
(Length of Discussion: 15 min) Tom Keane and See-Tong Pang discuss the results of a prospective clinical study utilizing a novel circulating tumor cells (CTC) blood assay to clarify PSA results in 200 men who present with a PSA of 4ng/ml-10ng/ml. The CellMax CTC Platform is used to isolate CTCs to assess NPV and PPV for Gray Zone patients. Isolated CTCs may also be analyzed for the presence of pro...